[1] Ozkaya N, Rosenblum M K, Durham B H, et al. The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort[J]. Mod Pathol, 2018,31(4):581-597.
[2] Tan A C S, Yzer S, Atebara N, et al. Three cases of Erdheim-Chester disease with intraocular manifestations:imaging and histopathology findings of a rare entity[J]. Am J Ophthalmol, 2017, 176:141-147.
[3] Emile J F, Diamond E L, Helias-Rodzewicz Z, et al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease[J]. Blood, 2014, 124(19): 3016-3019.
[4] Estrada-Veras J I, O'brien K J, Boyd L C, et al. The clinical spectrum of Erdheim-Chester disease: an observational cohort study[J]. Blood Adv, 2017, 1(6): 357-366.
[5] Haroche J, Arnaud L, Amoura Z. Erdheim-Chester disease[J]. Curr Opin Rheumatol, 2012, 24(1): 53-59.
[6] Haroche J, Cohen-Aubart F, Charlotte F, et al. The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm[J]. Expert Rev Clin Immunol, 2015, 11(9): 1033-1042.
[7] Swerdlow S H, Campo E, Pileri S A, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20): 2375-2390.
[8] Leonard J P, Martin P, Roboz G J. Practical implications of the 2016 revision of the World Health Organization Classification of lymphoid and myeloid neoplasms and acute leukemia[J]. J Clin Oncol, 2017, 35(23): 2708-2715.
[9] Toya T, Ogura M, Toyama K, et al. Prognostic factors of Erdheim-Chester disease: a nationwide survey in Japan[J]. Haematologica, 2018, 103(11): 1815-1824.
[10]Sung Y E, Lee Y S, Lee J, et al. Erdheim-Chester disease involving lymph nodes and liver clinically mimicking lymphoma: a case report[J]. J Pathol Transl Med, 2018,52(3):183-190.
[11]Franco-Palacios D, Mcdonald A, Aguillard R N, et al. An unusual case of interstitial lung disease in a patient with cardiopulmonary syndrome as the initial presentation of Erdheim-Chester disease[J]. BMJ Case Rep, 2017, 2017: bcr-2017-220659.
[12]Alotaibi S, Alhafi O, Nasr H, et al. Erdheim-Chester disease: case report with aggressive multisystem manifestations and review of the literature[J]. Case Rep Oncol, 2017, 10(2): 501-507.
[13]Pan Z, Kleinschmidt-Demasters B K. CNS Erdheim-Chester disease: a challenge to diagnose[J]. J Neuropathol Exp Neurol, 2017, 76(12): 986-996.
[14]Ortiz Salvador J M, Subiabre Ferrer D, Perez Ferriols A. Adult xanthogranulomatous disease of the orbit: clinical presentations, evaluation, and management[J]. Actas Dermosifiliogr, 2017, 108(5): 400-406.
[15]Ozkaya N, Rosenblum M K, Durham B H, et al. The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort[J]. Mod Pathol, 2018, 31(4): 581-597.
[16]Perez A, Crahes M, Laquerriere A, et al. Neurological form of Erdheim-Chester disease: case report and review of the literature[J]. Neurochirurgie, 2014, 60(6): 316-320.
[17]Martineau P, Pelletier-Galarneau M, Zeng W. The imaging findings of erdheim-Chester disease: a multimodality approach to diagnosis and staging[J]. World J Nucl Med, 2017, 16(1): 71-74.
[18]Oueriagli Nabih S. Erdheim-Chester disease and radiobiphosphonates bone scan: from a simple peripheral form to a rare axial location: a case report[J]. Tunis Med, 2016, 94(6): 167-171.
[19]Zanelli M, Smith M, Mengoli M C, et al. Erdheim-Chester disease: description of two illustrative cases involving the lung[J]. Histopathology, 2018, 73(1): 167-172.
[20]Nikonova A, Esfahani K, Chausse G, et al. Erdheim-Chester disease: the importance of information integration[J]. Case Rep Oncol, 2017, 10(2): 613-619.
[21]Ahuja J, Kanne J P, Meyer C A, et al. Histiocytic disorders of the chest: imaging findings[J]. Radiographics, 2015, 35(2): 357-370.
[22]DeMartino E, Go R S, Vassallo R. Langerhans cell histiocytosis and other histiocytic diseases of the lung[J]. Clin Chest Med, 2016, 37(3): 421-430.
[23]Mavrogenis A F, Igoumenou V G, Antoniadou T, et al. Rare diseases of bone: Erdheim-Chester and Rosai-Dorfman non-Langerhans cell histiocytoses[J]. EFORT Open Rev, 2018, 3(6): 381-390.
[24]Munoz J, Janku F, Cohen P R, et al. Erdheim-Chester disease: characteristics and management[J]. Mayo Clin Proc, 2014, 89(7): 985-996.
[25]Nordmann T M, Juengling F D, Recher M, et al. Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations[J]. Blood, 2017, 129(7): 879-882. |
